Diagnosing Variable Primary Aldosteronism.

Launched by QUEEN MARY UNIVERSITY OF LONDON · Mar 1, 2023

Keywords

ClinConnect Summary

This clinical trial, titled "Diagnosing Variable Primary Aldosteronism," is exploring how the body produces a hormone called aldosterone in people with a condition known as Primary Aldosteronism (PA), which can lead to high blood pressure. Researchers want to find out if there are patterns or changes in aldosterone levels throughout the day that could help in diagnosing this condition more accurately.

To join the study, participants should be between the ages of 65 and 74 and have symptoms suggesting they might have PA, such as low levels of a substance called renin in their blood or abnormal sodium and potassium levels. Those who have already been diagnosed with PA but have had aldosterone levels that are not typical for diagnosis might also qualify. Participants can expect to provide blood samples at different times to help researchers understand how aldosterone production varies. It’s important to note that people who are currently receiving certain medications or are in end-of-life care cannot participate. This study aims to improve how doctors diagnose PA, potentially leading to better treatment options for those affected.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • People with clinically suspected PA but have not met criteria for diagnosis. Suspicion based on low-renin (renin activity \<0.5 nmol/h/L or renin mass \<5 ng/L), plasma sodium \> 140mmol/L or plasma potassium \< 4mmol/L.
• • Patients who have been diagnosed with PA and had previous aldosterone samples \<277 pmol/L, a level which would normally not qualify for confirmatory testing.
• • Patients with aldosterone results done at different times that indicate variability in production.
• • Willing to consent and participate in the study.
• Exclusion Criteria:
• • Inability to withdraw β-adrenoceptor antagonist therapy for 2 weeks.
• • People on end of life treatment.